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background. Clostridium difﬁcile infection (CDI) is the most common cause of hospital-acquired infectious diarrhea.
objective. To analyze themethodological quality, content, and supporting evidence among clinical practice guidelines (CPGs) on CDI prevention.
design and setting. We searched medical databases and gray literature for CPGs on CDI prevention published January 2004-January
2015. Three reviewers independently screened articles and rated CPG quality using the Appraisal of Guidelines for Research and Evaluation II
(AGREE II) instrument, composed of 23 items, rated 1–7, within 6 domains. We reported each domain score as a percentage of its maximum
possible score and standardized range. We summarized recommendations, extracted their supporting articles, and rated individually the level of
evidence using the Oxford Centre for Evidence-Based Medicine Levels of Evidence.
results. Of 2,578 articles screened, 5 guidelines met inclusion criteria. Median AGREE II scores and interquartile ranges were: clarity of
presentation, 75.9% (75.9%–79.6%); scope and purpose, 74.1% (68.5%–85.2%); editorial independence, 63.9% (47.2%–66.7%); applicability,
43.1% (19.4%–55.6%); stakeholder involvement, 40.7% (38.9%–44.4%); and rigor of development, 18.1% (17.4%–35.4%). CPGs addressed
several common strategies for CDI prevention, including antibiotic stewardship, hypochlorite solutions, probiotic prophylaxis, and bundle
strategies. Recommendations were often not consistent with evidence, and most were based on low-level studies.
conclusion. CPGs did not adhere well to AGREE II reporting standards. Furthermore, there was limited transparency in moving from
evidence to recommendations. CDI prevention CPGs need to better adhere to AGREE-II and be transparent in moving from evidence to
recommendations, and recommendations need to be consistent with available evidence.
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Clostridium difﬁcile infection (CDI) is the most common cause
of hospital-acquired infectious diarrhea, and of increasing
concern in the community.1–3 Incidence of CDI varies by
country and between clinical settings, with rate and severity
recently increasing in high-income countries.4,5 CDI risk
depends on patient characteristics, such as older age6 and
antibiotic exposure.7–9 Symptoms of CDI range from mild
diarrhea to pseudomembranous colitis and toxic megacolon.2
Despite successful treatment rates, approximately 18%–20%
of patients experience recurrence within 8 weeks after the
ﬁrst episode.3
Canadian data estimate disease-attributable mortality as
approximately 5.3%–10% in endemic situations, and upwards
of 17% in outbreaks.1 In the United States, treating CDI cases
costs from $8,911 to $30,049 for primary infections, and
$13,655 to $18,067 for recurrences.10,11 To reduce CDI,
infection prevention and control has been emphasized, such as
through development and adherence to clinical practice
guidelines (CPGs).12 The CPGs aim to provide evidence-based
recommendations to facilitate decision-making, improve
patient care, and optimize resource use.13,14 Several organiza-
tions have published handbooks for CPG development
(eg, Institute of Medicine); however, studies show that they
are not often followed.15
Considerable morbidity, mortality, and costs are associated
with CDI; thus, guidelines on prevention and control, and the
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scientiﬁc evidence on which they are based, deserve close
evaluation. Our objectives were to conduct a systematic review
of the available CPGs on the prevention of CDI in order to
assess their quality, summarize their recommendations, and
evaluate the supporting evidence for each recommendation.
methods
Search Strategy
Using a comprehensive search strategy developed with a
librarian, we searched MEDLINE (1946–2015) and EMBASE
(1974–2015), using subject terms and key words, up to January
of 2015 (Supplemental Table 1). In addition, we searched 10
gray literature sources (studies published outside of major
medical databases) (Supplemental Table 2) and bibliographies
of included studies. There were no language or publication
status restrictions.
Inclusion Criteria
We included studies that: (1) were CPGs, deﬁned as documents
developed by a nationally recognized committee, publicly funded
institution, or medical society that provide recommendations for
the prevention of CDI; (2) contained a methodology section
(eg, study selection, evidence assessment); and (3) were de novo
CPGs, or the most updated version. We excluded guidelines
on prevention of hospital-acquired infections not speciﬁc to
C. difﬁcile. One reviewer (L.L.) screened titles and abstracts.
Using a standardized form, 2 reviewers (L.L., F.A.) indepen-
dently screened the full-text studies for eligibility. Disagreements
were resolved through consensus, and a third party (B.C.J.,
D.M.) was available.
Data Extraction and Quality Assessment
Three reviewers (B.S., F.A., L.L.) independently extracted
data using a standardized form and used the Appraisal of
Guidelines for Research and Evaluation II (AGREE II)
instrument to appraise CPG reporting.16 Before data abstrac-
tion, reviewers conducted calibration exercises with 2 experi-
enced methodologists (A.S., B.C.J.) to help ensure consistency
and validity between reviewers. The reviewers independently
rated CPGs based on 23 items, each on a 7-point Likert scale,
across 6 domains: (1) scope and purpose, (2) stakeholder
involvement, (3) rigor of development, (4) clarity of pre-
sentation, (5) applicability, and (6) editorial independence
(Supplemental Table 3).17 Item rating differences between
reviewers of 3 points or fewer were permitted. If not achieved,
a third party methodologist (B.C.J., D.M.) was consulted.
Additionally, each CPG was given a score of 1–7 and an
indication whether the reviewer would recommend using the
guideline (recommended, recommended with modiﬁcations,
not recommended).
Quality Appraisal of Evidence Used in Guidelines
One reviewer (L.L.) extracted recommendations for
prevention and control of CDI, with the strength of each
recommendation and evidence in support, when cited.
Ten percent of recommendations, with their supporting
evidence, were randomly selected and checked by a second
reviewer (B.S.). In 3 CPGs, articles referenced for recom-
mendations were extracted as reported. For 1 guideline
references were at the end of chapters,18 and for another from
supplement text,19 thus the reviewers came to consensus
regarding references used for speciﬁc recommendations.
Methods used by guideline authors to assign recommendation
strength and evaluate the evidence were extracted
(Supplemental Table 4). We used the 2011 Oxford Center
for Evidence-Based Medicine (OCEBM) Levels of Evidence
to rate the levels of evidence of each individual study supporting
each recommendation (Supplemental Table 5).20 Using
the OCEBM criteria, we modiﬁed the instrument on the
basis of study designs found in infection prevention and
control literature to facilitate rating of studies (Supplemental
Table 6). Extracted studies were rated 1 to 5, where 1
represents the highest level study (eg, meta-analysis of
randomized trials), and 5 represents the lowest level (eg,
ecological studies). The design could have been rated down
owing to study quality, imprecision, indirectness, or
inconsistency, or graded up if there were a large or very large
effect size.21
Data Analysis
Agreement for the full-text screening was calculated using
the kappa statistic and its 95% CI.22 For each guideline, we
calculated the AGREE II score for each domain as a percentage
of the maximum possible score and standardized range. We
considered 60% as a threshold of acceptable quality, as used in
previous studies.23 Across all CPGs, we calculated the median
domain score and interquartile range (IQR). Interrater agree-
ment for AGREE II scores was calculated using the intraclass
correlation coefﬁcient and its 95% CI.24 Agreement of 0.41–
0.60 was considered as moderate, 0.61–0.80 as substantial, and
0.81–1.00 as very good.25 All analyses were conducted using
Excel 2013 (Microsoft).
results
Search Results
After removing duplicates, 2,578 articles were screened, of
which 33 were reviewed in full-text (Figure 1). No additional
guidelines were found in gray literature, and all were available
from medical databases. Five CPGs were ultimately included
(kappa, 0.84 [95% CI, 0.53–1.00]). A third party (D.M.)
was consulted once. Reasons for excluding studies are detailed
in Figure 1.
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Guideline Characteristics
The included CPGs were developed by (1) the American
College of Gastroenterology (ACG),26 (2) the Association for
Professionals in Infection Control and Epidemiology
(APIC),18 (3) the European Society of Clinical Microbiology
and Infectious Disease,27 (4) the United Kingdom Health
Protection Agency/Department of Health (HPA/DH),19 and
(5) the Society for Healthcare Epidemiology of America/
Infectious Diseases Society of America (SHEA/IDSA)28
(Table 1). All were published between 2008 and 2014.
Although 4 were updated, 2 did not update prevention-related
information, thus their earlier version was used.19,27 Three
guidelines were from the United States,18,26,28 one from Europe
(11 countries),27,29 and one from the United Kingdom.19
Quality Appraisal of Guidelines
AGREE II scores are presented in Table 2. Overall reviewer
agreement was very good (intraclass correlation coefﬁcient,
0.88 [95% CI, 0.83–0.91]). Reviewers resolved all disagree-
ments amongst themselves. We did not contact guideline
authors for additional information because CPGs should be
stand-alone documents.
Domain 1: scope and purpose. The median score was
74.1% (IQR, 68.5%–85.2%), indicating that approximately
74% of the criteria for this domain were met. All CPGs met the
60% threshold. Limitations included insufﬁcient details about
the population, such as comorbidities and excluded
populations. Strategies for management of increased CDI
incidence or outbreaks were reported in all CPGs, though this
varied in coverage.
Domain 2: stakeholder involvement. The median score was
40.7% (IQR, 38.9%–44.4%), and no CPG scored above 60%.
Author panels included professionals from appropriate
disciplines but did not describe authors’ roles. Furthermore,
none of the CPGs sought the views of patients (eg, advocacy
groups). Lastly, only HPA/DH deﬁned target users
(eg, clinicians, trusts) and how they may use the CPG.19
Domain 3: rigor of development. This was the lowest
scoring domain, with a median of 18.1% (IQR,
17.4%–35.4%). No CPG scored above 60%. Only the
European Society of Clinical Microbiology and Infectious
Disease conducted a systematic search for evidence, although
study selection criteria were not speciﬁed.27 None of the
guidelines reported how recommendations were formulated
(eg, Delphi method),30 although SHEA/IDSA reports that
the ways of formulating recommendations were discussed in
the “consensus development methods” supplement.28 All
but APIC used an approach to assign strengths to their
recommendations based on the evidence available.18
Both ACG and SHEA/IDSA used a modiﬁed version of
Grading of Recommendations Assessment, Development and
Evaluation methods,26,28 the European Society of Clinical
Microbiology and Infectious Disease used a system by the
Healthcare Infection Control Practices Advisory Committee,27
and HPA/DH developed their own system (Supplemental
Table 4).19 Only the European Society of Clinical Microbiology
and Infectious Disease provided a transparent account of
their assessment of the scientiﬁc literature, using the 2008
OCEBM system.27 Guidelines mostly did not report how
evidence affected their development of recommendations
(eg, how low quality evidence resulted in strong
recommendations). Limitations of the body of evidence for
some recommendations were mentioned in SHEA/IDSA,
including “Although the quality of evidence to recommend
‘encourage appropriate use of antimicrobials’ to prevent CDI
does not meet level 1 criteria […] the CDI panel felt that
ﬁgure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses study ﬂow diagram. CPG, clinical practice guideline.
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appropriate antimicrobial use as a CDI prevention measure is
essential to any CDI prevention program.”28 In addition, HPA/
DH authors provided a detailed list of research gaps that need
to be addressed.19 Finally, only SHEA/IDSA stated a procedure
for updating the CPG.28
Domain 4: clarity of presentation. This domain obtained a
median score of 75.9% (IQR, 75.9%–79.6%). The only
CPG that did not meet the 60% threshold was APIC, which
did not clearly outline speciﬁc recommendations (ie,
recommendations were dispersed throughout text).18
Domain 5: applicability. The median score was 43.1%
(IQR, 19.4%–55.6%), with no CPGs scoring above 60%. The
most common issue was failing to address potential resource
implications (eg, costs) for guideline implementation,
followed by lack of detail about potential facilitators and
barriers to implementation. However, SHEA/IDSA included a
separate section regarding implementation strategies.28
Domain 6: editorial independence. The median score was
63.9% (IQR, 47.2%–66.7%), with 3 CPGs meeting the 60%
threshold.26–28 HPA/DH did not include information on
individual authors’ competing interests,19 and APIC had
industry sponsorship (a cleaning agent) that the reviewers
felt may have inﬂuenced the focus of the guideline.18
Overall evaluation. The overall median score for
guidelines was 4 out of 7 (IQR, 4-4). One CPG was
categorized as not recommended for use,26 and the other 4
were categorized as recommended, with modiﬁcations.
Limitations and suggested actions to improve guideline
quality are in Supplemental Table 7.
Guideline Recommendations
For all CPGs, authors searched for general CDI prevention
literature, rather than conducting systematic reviews based on
research questions. No CPG authors explained how evidence
was selected, or how recommendations were formulated from
the available literature. The median number of recommenda-
tions per guideline was 40 (range, 9–67), with 202 total recom-
mendations across all guidelines. Reviewers with knowledge of
infection prevention strategies (D.M., F.A., L.L.) discussed which
key strategies and individual recommendations to include.
Strategies were categorized as (1) education, (2) diagnosis and
surveillance, (3) antibiotic stewardship, (4) hand hygiene,
(5) patient isolation and personal equipment, (6) glove and
protective clothing use, (7) environmental cleaning, and
(8) novel strategies. Among the 8 categories, 22 key recom-
mendations were selected, included in some or all CPGs, totaling
76 recommendations across all CPGs. When available, each
recommendation’s status (recommended, not recommended,
unclear) and reviewer-assessed evidence using the OCEBM levels
were listed (Table 3). Additionally, recommendation strength
table 1. Characteristics Across Guidelines
Guidelines ACG (2013) APIC (2013) ESCMID (2009) HPA/DH (2008) SHEA/IDSA (2014)
Organization(s) ACG APIC ECDC, ESCMID NHS, PHE AHA, APIC, IDSA, SHEA
Country United States United States Europe United Kingdom United States
Source of funding None Industry No statement No statement Medical society
Novel publication or update Novel Update Novela Novela Update
No. of recommendations 9 19 40 93 25
NOTE. ACG, American College of Gastroenterology; AHA, American Hospital Association; APIC, Association of Professionals in Infection
Control and Epidemiology; DH, Department of Health; ECDC, European Centre for Disease Control; ESCMID, European Society for Clinical
Microbiology and Infectious Diseases; HPA, Health Protection Agency; IDSA, Infectious Diseases Society of America; NHS, National Health
Service; PHE, Public Health England; SHEA, Society for Healthcare Epidemiology of America.
aHas been updated; however, update does not include new information on prevention.
table 2. Methodological Quality of Included Guidelines: AGREE II Domain-Standardized Scores
AGREE domain ACG 2013 APIC 2013 ESCMID 2009 HPA/DH 2008 SHEA/IDSA 2014
Scope and purpose (%) 63.0 85.2 68.5 85.2 74.1
Stakeholder involvement (%) 38.9 27.8 40.7 44.4 50.0
Rigor of development (%) 18.1 15.3 48.6 17.4 35.4
Clarity of presentation (%) 75.9 53.7 88.9 79.6 75.9
Applicability (%) 4.2 58.3 19.4 55.6 43.1
Editorial independence (%) 77.8 47.2 63.9 30.6 66.7
Overall recommendation NR RWM RWM RWM RWM
NOTE. ACG, American College of Gastroenterology; AGREE II, Appraisal of Guidelines for Research and Evaluation II; APIC, Association
of Professionals in Infection Control and Epidemiology; DH, Department of Health; ESCMID, European Society for Clinical Microbiology
and Infectious Diseases; HPA, Health Protection Agency; IDSA, Infectious Diseases Society of America; NR, Not recommended;
RWM, Recommended, with modiﬁcations; SHEA, Society for Healthcare Epidemiology of America.
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table 3. Recommendations Across Guidelines, and Evidence Levels for Each Recommendation
RECOMMENDATION ACG 2013 APIC 2013 ESCMID 2009 HPA/DH 2008 SHEA/IDSA 2014
EDUCATION
Educate HCWs, staff, patients, and their families on CDI - ✓ ✓ ✓ ✓
2,3,4,5 4 3 2,3,4
DIAGNOSIS AND SURVEILLANCE
Only test diarrheal patients for C. difﬁcile, unless ileus present ✓ - ✓ ✓ ✓
4,5 4,5 5
Do not repeat testing, unless recurrence is suspected - - ✓ ✓ ✓
4,5
Determine baseline rate and threshold to identify high incidence - ✓ ✓ ✓ ✓
3,5 5 4 3,4
Store fecal samples from CDI cases for typing; compare isolates - - ✓a ✓a,b -
2,3,4 5
ANTIMICROBIAL STEWARDSHIP
Use antimicrobial stewardship; monitor CDI patients’ antibiotics ✓ ✓ ✓ ✓ ✓
3,4,5 3,4,5 2,3,4,5 2,3,4,5
Minimize prescription of high-risk antimicrobials - - - - ✓a
2,4
HAND HYGIENE
Use alcohol-based hand rubs - ✓ Xb X ✓
3,4,5 4,5 3,4,5 3,4,5
Use soap and water - ✓ ✓ ✓ ✓
3,4,5 3,4,5 3,5 3,4,5
Use soap and water only - ✓a - - ✓a
3,4,5
PATIENT ISOLATION AND PERSONAL EQUIPMENT
Suspected or known CDI patients should be in a private ✓ ✓ ✓ ✓ ✓
room or with other CDI patients 5 2,4,5 3,4 5
Isolation can be discontinued 48 hours after - - ✓ ✓ ✓
symptoms resolve 4,5 5 5
Isolate all patients with diarrhea while awaiting test result - ✓a - ✓a ✓a
4,5 5 5
Consider isolating CDI patient until discharge - ✓a - - ✓a
5 5
Cohorted patients should be managed by designated staff - ✓a ✓a - -
3,4
Use disposable equipment; dedicate ✓ ✓ ✓ -e ✓
nondisposable equipment 2d 3 2d,3,4,5 3,5
GLOVE AND PROTECTIVE CLOTHING USE
Gloves and gowns for staff of known or ✓ ✓ ✓ ✓ ✓
suspected CDI patient 3f 3,4,5 3,4,5 3,4
Gloves and gowns for visitors of known or ✓ ✓ - ✓ U
suspected CDI patient 3f 2,4,5 2
ENVIRONMENTAL CLEANING
Use EPA registered disinfectant with C. difﬁcile-sporicidal label ✓g ✓ ✓ ✓ ✓h
claim or 1,000 ppm chlorine-containing cleaning agents 3,4,5 2,3,4,5 3,4,5 3,4,5 4
Use bleach solution for daily disinfection and discharge cleaning - ✓a - ✓a Ua
2,3,4,5 3,4,5 4
NOVEL STRATEGIES
Use of alternate methods of disinfection (ultraviolet light, HPV) - ✓a - ✓a Ua
3,4,5 4 3,4,5
Use probiotics for prophylaxis X - U X U
2 1,2 1,2 1,2
NOTE. ACG, American College of Gastroenterology; APIC, Association of Professionals in Infection Control and Epidemiology;
CDI, Clostridium difﬁcile infection; DH, Department of Health; EPA, Environmental Protection Agency; ESCMID, European Society for Clinical
Microbiology and Infectious Diseases; HCWs, healthcare workers; HPA, Health Protection Agency; HPV, hydrogen peroxide vapor;
IDSA, Infectious Diseases Society of America; SHEA, Society for Healthcare Epidemiology of America.
✓ Recommended
X Not recommended
U Unclear
- Not mentioned
a Recommendation speciﬁc for a high incidence/outbreak environment
b Storage of fecal samples in non-outbreak settings is recommended.
c Alcohol-based hand rubs should not be the only hand hygiene measure.
d Disposable thermometers only.
e No speciﬁc recommendation, but discusses link to personal equipment and C. difﬁcile spread, and association of using disposable thermo-
meters and reductions in CDI.
f Glove use only.
g 5,000 ppm or greater.
h Data are conﬂicting as to whether inactivation of spores is necessary to prevent C. difﬁcile transmission, especially in an endemic setting.
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and author-assessed evidence were compared with the reviewer-
assessed evidence (Supplemental Table 8).
Quality Appraisal of Underlying Evidence
For 76 recommendations, 180 unique studies were cited. Most
CPG authors referenced previously conducted strategy-
speciﬁc reviews or guidelines (eg, hand hygiene, isolation
precautions). These reviews were not always systematic, and
were published in 2007 or earlier.18,26,28 Most evidence was
before-after studies, and there were very few controlled
trials. To support individual strategies, studies implementing
“bundle” strategies (ie, multiple interventions) and/or those
conducted to control outbreaks were cited, which introduces
bias. Only 2 randomized controlled trials with CDI incidence
as an outcome were found; one assessed the impact of treating
asymptomatic patients, and the other evaluated using
reusable thermometers. Only 1 strategy was supported by
a meta-analysis of randomized controlled trials, probiotics
prophylaxis, which had more than 20 studies.31
discussion
Among the 5 CPGs identiﬁed, we found that although the
recommendations were similar across guidelines, they were
developed inconsistently, and each had considerable metho-
dological limitations. On the basis of AGREE II standards, no
CPG met quality thresholds for all 6 domains. Scores for rigor
of development, stakeholder involvement, and applicability
were the poorest. There were insufﬁcient links between
recommendations and supporting evidence, and CPGs were
not transparent about how the limitations of the evidence
impacted their recommendations, albeit with some exceptions
as described in the SHEA/IDSA guideline.28
The rigor of development domain scored low across CPGs.
For guidelines to be good-quality and trustworthy, they are
contingent on clear research questions and systematic
reviews.30 None of the CPGs outlined their questions a priori,
and only 1 guideline conducted a systematic review, though
with limitations (eg, no inclusion/exclusion criteria, no
screening results).27 Internationally accepted guideline
standards (eg, Grading of Recommendations Assessment,
Development and Evaluation; AGREE) suggest a priori ques-
tions and structured searches. For example, “For hospitalized
patients with suspected or conﬁrmed CDI, does [prevention
strategy] compared with [no prevention or alternative strat-
egy] reduce CDI incidence?” Guideline authors underutilized
available evidence for drafting recommendations. Four CPGs
conducted quality of evidence assessments; however, only 1
was transparent.27 Despite poor reporting (ie, transparency) of
evidence to recommendations, and incongruence between
evidence quality and recommendations, recommendations
were mostly consistent across guidelines. Strong recommen-
dations were often made from low-level evidence without
justiﬁcation (Table 2). The prevention strategy with the
highest-level evidence, probiotics, was “not recommended”
or “unresolved.” This may suggest that guideline panels
depended on nonsystematic, informal consensus-based
methods to develop recommendations.
The applicability domain was also poorly addressed,
particularly regarding costs and implementation barriers/
facilitators. SHEA/IDSA had a very comprehensive strategy for
CPG implementation,28 suggesting that more recent guidelines
are recognizing its importance. It is critical, however, that
guidelines should be rigorously developed before considering
their application.
The editorial independence domain scored well, although
no guideline was led by an unconﬂicted methodologist, the
gold standard methodology.32 Among the reported statements
for individual authors’ potential conﬂicts of interest, there
were no ﬁnancial conﬂicts. Reporting of intellectual conﬂicts
was limited. There was a conﬂict of interest issue in APIC,
where the source of funding was Clorox, a sodium
hypochlorite cleaning products company.18 This may have
inﬂuenced recommendations because its focus was cleaning
strategies centered around hypochlorite solutions, whereas
SHEA/IDSA reported this as an area of controversy.28
In evaluating evidence behind the recommendations, there
were 3 major limitations. First, most were quasi-experimental
studies, which have numerous potential biases, including
maturation effects, selection bias, and confounding.33 Second,
interventions were often conducted during outbreaks, which are
vulnerable to regressing to the mean.34 Third, “bundle” strategies
—that is, multiple interventions, were common. Although such
studies may be conducted owing to feasibility,33 guidelines are
extrapolated to individual strategy effectiveness based on these
studies. None of the guidelines discussed how limitations in the
overall body of evidence impacted their decisions assigning
strengths of recommendations. Although there a number of
handbooks on CPG methodology,35 adherence by guideline
development groups is low across numerous disease areas.36
To our knowledge, this is the only critical appraisal of
infection prevention and control CPGs. Previous reviews
of CPGs for other diseases reported similar limitations,
particularly rigor of development, applicability, and editorial
independence.37,38 Notably, other guideline reviews have
remarked on the similarity of recommendations across
guidelines despite considerably different methodologies.39
A possible reason may be that CPGs are still reliant on
expert-based recommendations, supported by selective
evidence rather than systematically searched evidence. The
current gold standard for recommendation development,
Grading of Recommendations Assessment, Development and
Evaluation, was used in only 2 guidelines and was considerably
modiﬁed in both (Supplemental Table 4).26,28
Two narrative reviews on CDI prevention and control
studies similarly commented on limitations of the available
literature—for example, lack of randomized controlled trials
and controlled time-series designs, as well as the tendency to
implement multiple strategies to control outbreaks.40,41 As in
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many medical subspecialties, it is worthwhile to note that large
randomized controlled trials are a relatively recent phenomenon
among infection control literature. However, in the absence of
high-quality evidence, poor or indirect evidence could be used,
and authors should be transparent about limitations and how this
impacted recommendations’ development. It has been suggested
that when there is poor quality evidence, this is where clinicians
need CPGs the most.30 A novel decision support tool to assist
guideline developers to systematically and transparently develop
recommendation from available evidence has been proposed.42
Our study had some limitations. First, although AGREE II is
a robust guideline appraisal instrument,43 the quality might
have been underestimated owing to incomplete reporting.
However, there is agreement that transparent reporting of
methodology is key for creating trustworthy guidelines.44
Second, we used the 2011 OCEBM Levels of Evidence instru-
ment to rate the evidence for each recommendation, which is a
crude measure and does not account for variability in quality
across similar study designs. We attempted to account for
this by modifying ratings to accommodate the types of
quasi-experimental studies encountered. For example, we
considered that an interrupted time series study with
a historical control was a level 3 study, whereas a prospective
interrupted time series with a concurrent control was level 2.
However, there are criteria where low quality evidence
can warrant a strong recommendation.45 For example, when
evidence is low for beneﬁt of a particular strategy, but high for
harm of not implementing any strategy (eg, terminal cleaning
of CDI patients’ rooms), a strong recommendation is justiﬁed.
Third, we checked only 10% of data for the recommendations
(8/76 individual CPG recommendations); however, the second
reviewer did not ﬁnd differences in the extractions, thus we
feel conﬁdent in our methodological approach.
Our study also had several strengths. First, we conducted a
comprehensive search, including both medical databases and
10 gray literature sources. Second, 3 reviewers appraised each
guideline, each with either methodology or clinical expertise,
and the team had high concordance in AGREE II scores. Third,
we analyzed the cited evidence underlying each recommen-
dation, which has rarely been evaluated for CPGs.46
In summary, there is a considerable need for high quality
CPGs because they are often used for patient care. Research
suggests that CPGs may reduce inappropriate practices, bridge
the gap of research and clinical application, and improve
overall quality and safety of healthcare services.30 Future
guidelines of CDI prevention should be developed using vali-
dated methodological standards. Furthermore, there is a need
for higher quality primary research on this topic, to better
inform recommendations.
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